abstract |
Compounds that act as potent antagonists of the CCR9 receptor are provided. Animal tests demonstrate that these compounds are useful for treating inflammatory, characteristic diseases of CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods of treatment of CCR9-mediated diseases, and as a control in tests for the identification of CCR9 antagonists. |